Updated on 18 November 2013
The changes have been made to support BMS’ ongoing success as a biopharma leader
Singapore: Bristol-Myers Squibb (BMS) has made a series of related changes within its senior management team. To support its ongoing success as a biopharma leader, the company is evolving its business model, creating a global integrated commercial organization and expanding the scope of its finance organization.
Mr Giovanni Caforio has been appointed executive vice president and chief commercial officer, a newly created position in which he will lead all of the company's commercial units across all geographies. Mr Caforio will be responsible for the global commercial strategy of the company and for the performance of the company's commercial operations worldwide. Caforio was most recently president, US.
Mr Charles Bancroft, executive vice president and chief financial officer, will take on an expanded role that includes the business development and strategy groups. Mr Bancroft will be responsible for developing an integrated approach to finance, business development and strategy that will enhance the company's effectiveness in meeting its long-term goals.
Mr Murdo Gordon has been appointed president, US, and will report to Mr Caforio. Mr Gordon was most recently senior vice president, US Oncology.
Mr Beatrice Cazala, executive vice president, commercial operations in charge of global commercialization, Europe and China, is in the process of transitioning to a new role within the company.
Mr Lamberto Andreotti, CEO, BMS, said that, "By evolving our organization and expanding the roles of Giovanni and Charlie, I feel even more confident in the strength of my management team and our ability to take advantage of the most critical opportunities to build long-term sustainable growth."